- Home
- GSBC vs MBX Comparison
GSBC vs MBX Comparison
Compare GSBC & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- MBX
- Stock Information
- Founded
- GSBC 1923
- MBX 36
- Country
- GSBC United States
- MBX United States
- Employees
- GSBC N/A
- MBX N/A
- Industry
- GSBC Major Banks
- MBX
- Sector
- GSBC Finance
- MBX
- Exchange
- GSBC Nasdaq
- MBX NYSE
- Market Cap
- GSBC 705.4M
- MBX 644.6M
- IPO Year
- GSBC N/A
- MBX 2024
- Fundamental
- Price
- GSBC $59.07
- MBX $10.93
- Analyst Decision
- GSBC Hold
- MBX Strong Buy
- Analyst Count
- GSBC 2
- MBX 4
- Target Price
- GSBC $61.00
- MBX $37.25
- AVG Volume (30 Days)
- GSBC 35.4K
- MBX 292.8K
- Earning Date
- GSBC 01-21-2025
- MBX 02-16-2025
- Dividend Yield
- GSBC 2.75%
- MBX N/A
- EPS Growth
- GSBC N/A
- MBX N/A
- EPS
- GSBC 5.26
- MBX N/A
- Revenue
- GSBC $216,992,000.00
- MBX N/A
- Revenue This Year
- GSBC N/A
- MBX N/A
- Revenue Next Year
- GSBC $4.75
- MBX N/A
- P/E Ratio
- GSBC $11.07
- MBX N/A
- Revenue Growth
- GSBC N/A
- MBX N/A
- 52 Week Low
- GSBC $48.19
- MBX $9.42
- 52 Week High
- GSBC $68.02
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- GSBC 42.64
- MBX N/A
- Support Level
- GSBC $58.79
- MBX N/A
- Resistance Level
- GSBC $60.91
- MBX N/A
- Average True Range (ATR)
- GSBC 1.97
- MBX 0.00
- MACD
- GSBC 0.03
- MBX 0.00
- Stochastic Oscillator
- GSBC 30.76
- MBX 0.00
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.